Jury orders Natera to pay $44.9M in damages to CareDx for false advertising

A jury ruled that Natera owes $44.9 million in damages to CareDx on grounds that Natera intentionally mislead the transplant community regarding its Prospera Kidney Transplant Technology by likening it to CareDx’s AlloSure test; the jury also ruled that CareDx engaged in two accounts of false advertising.